Cristobal, IonManso, RebecaRincon, RaulCarames, CristinaSenin, ClaraBorrero, AureaMartínez-Useros, JavierRodriguez, MariaZazo, SandraAguilera, OscarMadoz-Gurpide, JuanRojo, FedericoGarcía-Foncillas, Jesus2024-01-302024-01-302014-04-011535-7163https://hdl.handle.net/10115/29235Artículo publicado en 2014 https://aacrjournals.org/mct https://aacrjournals.org/mct/article/13/4/938/91645/PP2A-Inhibition-Is-a-Common-Event-in-Colorectal DOI: 10.1158/1535-7163.MCT-13-0150 La revista está indexada en: Science Citation Index Expanded (Clarivate), Scopus (ELSEVIER), PASCAL, BIOSIS (Clarivate), Biotechnology Research Abstracts (ProQuest), Chemical Abstracts Core (American Chemical Society), EMBASE (ELSEVIER), MEDLINE (United States National Library of Medicine) Molecular Cancer Therapeutics publica estudios de investigación traslacional centrados en el descubrimiento y desarrollo preclínico de agentes terapéuticos para oncología. Pertenece a la AACR (American Association of Cancer Research) que fue fundada el 7 de mayo de 1907 en Washington, D.C.. ISSN: 1535-7163, EISSN: 1538-8514. En el año 2014 esta revista tuvo un total de 16,563 citas. -JCR: Tiene la clasificación de ONCOLOGY SCIENCES donde se sitúa en la posición 23 de 211 revistas en el año 2014. Con un índice de impacto JCR (2014) de 5.683; y un índice de impacto a 5 años de 5.895. Eigenfactor Score: 0.03995. Con un JIF percentil de 89.34 pertenece al Q1. -SCOPUS: Tiene la clasificación de ONCOLOGY donde se sitúa en la posición 23 de 310 revistas en el año 2014. Situada en un percentil 92 que pertenece al D1. -Número de citas a 22/12/2023 del artículo según Web of science: 84; y según Crossref: 97. Y el número total de visualizaciones: 886. El número de citas según SCOPUS es de 99 y Según Google Schoolar: 130. -CiteScore en 2014 es de 10.0Protein phosphatase 2A (PP2A) is a tumor suppressor that regulates many signaling pathways crucial for cell transformation. In fact, decreased activity of PP2A has been reported as a recurrent alteration in many types of cancer. Here, we show that PP2A is frequently inactivated in patients with colorectal cancer, indicating that PP2A represents a potential therapeutic target for this disease. We identified overexpression of the endogenous PP2A inhibitors SET and CIP2A, and downregulation of regulatory PP2A such as PPP2R2A and PPP2R5E, as contributing mechanisms to PP2A inhibition in colorectal cancer. Moreover, we observed that its restoration using FTY720 impairs proliferation and clonogenic potential of colorectal cancer cells, induces caspase-dependent apoptosis, and affects AKT and extracellular signal-regulated kinase-1/2 activation status. Interestingly, treatment with FTY720 showed an additive effect with 5- fluorouracil, SN-38, and oxaliplatin, drugs used in standard chemotherapy in patients with colorectal cancer. These results suggest that PP2A activity is commonly decreased in colorectal cancer cells, and that the use of PP2A activators, such as FTY720, might represent a potential novel therapeutic strategy in colorectal cancer. Mol Cancer Ther; 13(4); 938–47. 2014 AACR.engPP2A Inhibition Is a Common Event in Colorectal Cancer and Its Restoration Using FTY720 Shows Promising Therapeutic Potentialinfo:eu-repo/semantics/article10.1158/1535-7163.MCT-13-0150info:eu-repo/semantics/restrictedAccess